Mizuho lowered the firm’s price target on Axsome Therapeutics to $90 from $100 and keeps a Buy rating on the shares. The analyst cites higher spending and updated gross margin assumptions for the Q3 report for the target drop.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM:
- Axsome Therapeutics Inc. Reported Earnings. Did it Beat Estimates?
- Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Axsome Therapeutics reports Q3 EPS ($1.32), consensus ($1.19)
- Axsome Therapeutics Inc. (AXSM) Q3 Earnings Cheat Sheet
- Axsome announces it will help raise awareness of Alzheimer’s disease
